Drugs / IL13Ralpha2 CAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04119024 | Oct 2025 → Oct 2026 expected | acral lentiginous melanoma, adrenal cortex carcinoma, breast cancer, head and neck squamous cell carcinoma +9 | Anusha Kalbasi | Recruiting | No outcome recorded |
| Phase 1 | NCT04661384 | Mar 2021 → Jan 2027 expected | ependymoma, glioblastoma, malignant leptomeningeal tumor, medulloblastoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL13Ralpha2-CAR T cells | “Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1.” NCT04661384 ↗1“The study agent is called IL13Ralpha2 CAR T cells.” NCT04119024 ↗ |
| Action | Deplete | “engineered to destroy brain tumor cells in the laboratory” NCT04661384 ↗ |
| Modality | Cell therapy | “CAR T cells” NCT04119024 ↗ |
| Route | Intravenous | “Patients then receive IL13Ralpha2 CAR T cells IV on day 0.” NCT04119024 ↗ |
| Target | IL13RA2 | “This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2.” NCT04119024 ↗ |